![Despite Headwinds, Biosimilars Market Is Growing in 2024](https://getmga.com/wp-content/uploads/2024/07/iStock-1272520901-1080x675.jpg)
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
Politicians—Democrats and Republicans alike—regularly complain about high drug prices and the need for policy changes to make prescription medicines more affordable for patients (read: voters).
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.